Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Amnesia, Cognitive disorder
Clinical narrative: Arriving at the lot she 'was unable to identify where I was, what I had been doing'. In short she was amnestic; She later determined that she was given two muffins; thus there was a cognitive element; This spontaneous case was reported by a physician and describes the occurrence of AMNESIA (Arriving at the lot she 'was unable to identify where I was, what I had been doing'. In short she was amnestic) and COGNITIVE DISORDER (She later determined that she was given two muffins; thus there was a cognitive element) in a 77-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 (Patient was diagnosed with Covid 19) on 19-Aug-2022.    On 10-Nov-2023, the patient received fifth dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (Intramuscular use) .5 milliliter. On 10-Nov-2023, the patient experienced AMNESIA (Arriving at the lot she 'was unable to identify where I was, what I had been doing'. In short she was amnestic) (seriousness criterion medically significant) and COGNITIVE DISORDER (She later determined that she was given two muffins; thus there was a cognitive element) (seriousness criterion medically significant). On 10-Nov-2023, AMNESIA (Arriving at the lot she 'was unable to identify where I was, what I had been doing'. In short she was amnestic) and COGNITIVE DISORDER (She later determined that she was given two muffins; thus there was a cognitive element) had resolved.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Intramuscular use), the reporter did not provide any causality assessments.   Concomitant medications were not reported.  Patient left the pharmacy immediately after receiving vaccine, walked to her car and moved it from the street parking to a lot which was three minutes removed. Arriving at the lot she 'was unable to identify where she was, what she had been doing'. In short, she was amnestic. She was able to dial her friend's number (also an MD) and identify her memory loss. The dialing and speech were unimpaired, and she was without headache or arm or leg or visual issues. She remained in her car for 30 plus minutes and walked 200 feet to a local bakery; ordered "two croissants". She later determined that she was given two muffins; thus, there was a cognitive element. The spell, recalled in entirety, ceased within 45 minutes without residue. No treatment information was provided by the reporter.  Company Comment: This spontaneous case concerns a 77-year-old female patient with no relevant medical history reported, who experienced the unexpected, serious (medically significant), events of amnesia and cognitive disorder, on the same day after the fifth dose of mRNA-1273.815 (SPIKEVAX 2023-2024). It was reported that patient left the pharmacy immediately after receiving vaccine, walked to her car and moved it from the street parking to a lot which was three minutes removed. Arriving at the lot she 'was unable to identify where she was, what she had been doing'. In short, she was amnestic. She was able to dial her friend's number (also an MD) and identify her memory loss. The dialing and speech were unimpaired, and she was without headache or arm or leg or visual issues. She remained in her car for 30 plus minutes and walked 200 feet to a local bakery; ordered "two croissants". She later determined that she was given two muffins; thus, there was a cognitive element. The spell, recalled in entirety, ceased within 45 minutes without residue. No further clinical information was provided for review. The patient's age could be a confounder for the events. The benefit-risk relationship of mRNA-1273.815 (SPIKEVAX 2023-2024) vaccine is not affected by this report.